Andrea Denicoff, RN, MS, ANP Clinical Investigations Branch, CTEP, DCTD CTEP Program Meeting March 18, 2009 CTEP Phase III Cancer Treatment Trials with.

Slides:

Advertisements

Similar presentations

Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.

Advertisements

Martin E. Gutierrez, MD Recruitment Experience in a Phase 0 Trial of ABT-888, an Inhibitor of Poly (ADP- ribose) Polymerase (PARP), in Patients With Advanced.

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Amylou C. Dueck (Mayo Clinic)

Needs assessment of cancer survivors O Santin, L Murray, A Gavin and M Donnelly Cancer health services research and survivorship studies programme Centre.

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Living with and beyond treatment for cancer – the challenge for secondary care Nigel Acheson Medical Director Peninsula Cancer Network.

Presented by: Deb Bulych, Director Supportive Care Patient Reported Outcomes (PRO)

Hematology/Oncology Fellowship Kristie A. Blum, M.D. Gregory Otterson, M.D. The Ohio State University Department of Medicine, Division of Hematology &

Accomplishments & Outcomes: Genomics Successes in Oregon Amy Zlot Oregon Genetics Program.

Documentation for Acute Care

BEACON IMPLEMENTATION CTG UPDATE Seth Bokser, MD Noori Dhillon, Beacon Project Manager.

Cancer Program Standards 2012: Ensuring Patient-Centered Care

Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.

A Survey of Quality of Life Following Surgery for Malignant Pleural Mesothelioma: Reflects the patients’ commitment to Learning about the Disease D A Raffle,

Paula Peyrani, MD Medical/Project Director, HIV Program at the 550 Clinic Assistant Director, Research Design and Development Clinical and Translational.

Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.

A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a.

CTEP, NCI Adverse Event Reporting Programmatic & Workflow Processes Prepared by: Ann Setser May 24, 2010.

Study Designs Afshin Ostovar Bushehr University of Medical Sciences Bushehr, /4/20151.

Effective Presentation of Study Results How are RCTs presented in abstracts & publications? and Some things to consider in your own presentations NCIC.

Predictors of Cancer-related Pain Improvement over 12 Months Hsiao-Lan Wang, PhD, RN, CMSRN, HFS Assistant Professor University of South Florida September,

A Glimpse of the Science Behind the American Cancer Society Access to Care Campaign Impact of Being Uninsured or Underinsured on Individuals with Cancer.

1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.

Evidence-Based Medicine Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department of.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.

QUALITY of LIFE Head & Neck Cancer and Chemotherapy Lisa Licitra Head and Neck Medical Oncology Unit Istituto Nazionale Tumori Milano.

Cancer Disparities Research Partnership (CDRP): Linking University & Community Radiation Oncology to Improve Cancer Outcomes Patrick D. Maguire, M.D. New.

Intensity-Modulated Radiotherapy is Associated with Improved Global Quality of Life Among Long-Term Survivors of Head and Neck Cancer Allen M. Chen, M.D.,

Arthritis Advisory Committee March 4, 2003 Update on the Safety of TNF Blockers Li-ching Liang, M.D. FDA / CBER/ OTRR Arthritis Advisory Committee March.

Acknowledgements This report differs from the submitted abstract due to further subdivision of patients into analytic and non- analytic, and focus on the.

FDA’s Public Workshop: Innovative Systems for Delivery of Drugs and Biologics: Scientific, Clinical, and Regulatory Challenges Paul Goldfarb, MD, FACS.

Kang Y et al. Proc ASCO 2010;Abstract LBA4007.

Quality of Life (QOL) & Patient Reported Outcomes (PRO) Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research Group, DCP, NCI, NIH,

Cancer “whiteboard” presentation ●Name of cancer (what type), where can it occur? ●Function of body part that it affects ●Causes (genetic, environmental…)?

CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

National Cancer Survivorship Initiative 2010 Update.

T. Hijal MD, A. Al Hamad MD, N. Khalaf, K. Sultanem MD, S. Faria MD and T. Muanza MD McGill University, Department of Radiation Oncology, Montréal, Québec,

FRENCH high-resolution studies - Breast cancer: 1990, 1997, 2003, 2010 ? - Colorectal cancer: 1990, 1995, 2000, 2005, 2010 ? - Prostate cancer: 1995,

CON - 1 Conclusions C David R. Parkinson Vice President, Global Head, Clinical Research and Development Novartis Pharmaceuticals Corporation.

Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.

CoRPS Center of Research on Psychology in Somatic diseases Multiple myeloma survivors experience a low quality of life and many disease-specific complaints:

The Cancer Registry of Norway Jan F Nygård Head of the IT-department.

Performing a Successful Supportive Care Clinical Trial Jennifer Temel, MD.

CoRPS Nice Center of Research on Psychology in Somatic diseases Quality of life and symptom assessment in long-term blood cancer survivors (chapter.

CoRPS London 26 & 27 October 2010 Center of Research on Psychology in Somatic diseases Understanding PRO in hematological disorders: Do we have a consensus?

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase III MF07-01 Trial: Impact of Initial Local Resection on Stage.

SWAG SSG Skin Meeting Thursday 22nd September 2016 Maxine Taylor

Patient Focused Drug Development An FDA Perspective

NVALT25/ELDAPT Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy.

Evidence-based Medicine

Table 1: Patient Demographics

1st International Online BioMedical Conference (IOBMC 2015)

CCO Independent Conference Coverage

In Focus 6 Spotlight on Specific Cancers TANYA

Prevalence of Venous Thromboembolism in Cancer Patients in the Emergency Department and associated Healthcare Resource Utilization and Expenditure.

Results: Patient details Results: QoL

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Innovative Approaches to Clinical Trials

11/20/2018 Study Types.

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

CDK4/6 Inhibitors in Breast Cancer:

Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

A Proposed Taxonomy of Terms to Guide the Clinical Trial Recruitment Process Neil A. Hagen, MD, FRCPC, Jackson S. Wu, MD, FRCPC, Carla R. Stiles, BN

Richard J Gralla, MD, Frank Griesinger, MD, PhD

The Development of an International Registry

The Power of As-Treated Analyses

Presentation transcript:

Andrea Denicoff, RN, MS, ANP Clinical Investigations Branch, CTEP, DCTD CTEP Program Meeting March 18, 2009 CTEP Phase III Cancer Treatment Trials with PROs & HRQOL Endpoints

Purpose Describe the breadth of currently active Phase III NCI-supported disease treatment trials that include HR-QOL secondary endpoints and compare the characteristics of these trials with those implemented in the early 1990s.* *Nayfield S, Hailey BJ, McCabe M: Quality of life assessment in cancer clinical trials. Report of the Workshop on Quality of Life Research in Cancer Clinical Trials, July 16-17, Bethesda, MD: US Department of Health and Human Services, 1991.

Methods A search was conducted in May 2008 of NCI’s CTEP clinical trials database using the terms: –Active cancer treatment trial –Phase III trial –QOL endpoint –Protocol title –Lead cancer/disease –QOL instrument name PRO & HRQOL instruments were grouped according to their primary measurement focus under the headings: –General QOL (EQ-5D, MOS, PEDSQL 4.0) –Cancer-Specific QOL (FACT, EORTC) –Functional Assessments (CPT, CVLT, WRAT) –Pain & Symptom Management (BPI, MDASI) –Depression/Other Emotional States (BASC, HADS)

Results: 1990 vs Active Phase III Clinical Trials Cancer Type 1990 Number of Trials 2008 Number of Trials Pediatric Tumors47 Breast38 GYN24 Lung25 Hematologic22 Bladder10 Head & Neck12 Prostate19 Colorectal04 Myeloma03 Melanoma01 Metastases01 Trials with QOL components 1646 Pediatric vs. Adult4 / 127 / 39 Different QOL Tools961

PRO & HRQOL Instruments: 2008 Percentage by Primary Measurement Focus

Most Commonly Used Instruments in Active 2008 Phase III Treatment Trials

Numbers of QOL Instruments Used in Active 2008 Phase III Trials * Neurotox Assmt: includes measures of neurocognitive function, neurotoxicities QOL Tools Used per Trial QOL w/ Neurotox Assmt* QOL w/out Neurotox Assmt* # of Trials Adult Average # of Tools Adult # of Trials Pediatric 752 Average # of Tools Pediatric

Results Since 1990, there has been a 3-fold increase in the number of trials with a QOL endpoint along with a 3-fold increase in QOL measurement tools. 62 instruments are being used in these trials to assess the patient’s perspective; often multiple measures are used in a single trial (172 used in total including subtypes). 66 instruments/subtypes are found in the 7 pediatric trials, accounting for 38% of the total amount seen in these trials. Of the 46 trials, the FACT and its various disease and symptom subscales (lung, neurotoxicity, etc.) are used the most frequently (21%).

Conclusions In addition to assessing HRQOL and PRO differences among treatment arms in phase III trials, more tools are being used to measure the effects of cancer treatment on function. With the increased use of symptom-specific assessments on trials, there has been a subsequent increased attention on ways to use these data to develop intervention trials. This will lead to improved QOL for patients, as well as assist clinicians and patients in the treatment decision making process.